The immunogenetics of Neurological Disease.
This article is protected by copyright. All rights reserved. PMID: 29159928 [PubMed - as supplied by publisher]
ConclusionsThe length of the striatal region uptake is clinically useful and highly valuable to confirm dopaminergic degeneration “in vivo” as an aid to the diagnosis of Parkinson’s disease. It compares fairly well to the standard uptake ratio-based features, reaching, at least, similar accuracies and is easier to obtain automatically. Thus, we propose its day to day clinical use, jointly with the uptake ratio-based feat ures, in the computer-aided diagnosis of dopaminergic degeneration in Parkinson’s disease.
ConclusionsThese results highlight the new concept that combined A β and tau thresholds can predict imminent neurodegeneration as an alternative framework with a high statistical power for testing the effect of disease-modifying therapies on [18F]FDG uptake decline over a typical 2-year clinical trial period in individuals with preclinical AD.
ConclusionsBrain uptake of [18F]PSS232 matched the distribution of mGlu5 and followed a two-tissue compartment model. The well-defined kinetics and the possibility to use reference tissue models, obviating the need for arterial blood sampling, make [18F]PSS232 a promising fluorine-18 labeled radioligand for measuring mGlu5 density in humans.
Afzal Javed, Asha Charles
AbstractPurpose of ReviewThis review aims to survey recent trends in electrical forms of neuromodulation, with a specific application to Parkinson ’s disease (PD). Emerging trends are identified, highlighting synergies in state-of-the-art neuromodulation strategies, with directions for future improvements in stimulation efficacy suggested.Recent FindingsDeep brain stimulation remains the most common and effective form of electrical stimulation for the treatment of PD. Evidence suggests that transcranial direct current stimulation (tDCS) most likely impacts the motor symptoms of the disease, with the most prominent re...
AbstractPurpose of reviewThis review will examine the current evidence that genetic and/or epigenetic variation may influence the multiple sclerosis (MS) clinical course, phenotype, and measures of MS severity including disability progression and relapse rate.Recent findingsThere is little evidence that MS clinical phenotype is under significant genetic control. There is increasing evidence that there may be genetic determinants of the rate of disability progression. However, studies that can analyse disability progression and take into account all the confounding variables such as treatment, clinical characteristics, and ...
Publication date: Available online 23 April 2018 Source:Stem Cell Research Author(s): Michael Peitz, Tamara Bechler, Catrin Cornelia Thiele, Monika Veltel, Melanie Bloschies, Klaus Fliessbach, Alfredo Ramirez, Oliver Brüstle Alzheimer's disease (AD) is most the frequent neurodegenerative disease, and the APOE ε4 allele is the most prominent risk factor for late-onset AD. Here, we present an iPSC line generated from peripheral blood cells of a male AD patient employing Sendai virus vectors encoding the transcription factors OCT4, SOX2, KLF4 and c-MYC. The characterized iPSC line expresses typical human pluripo...
New guidelines update guidance on starting, switching, and stopping disease-modifying therapies in multiple sclerosis and recommend an earlier, rather than later, start to treatment.Medscape Medical News
The relationship between dopamine receptor blockade and cognitive performance in schizophrenia: a [11C]-raclopride PET study with aripiprazole, Published online: 24 April 2018; doi:10.1038/s41398-018-0134-6The relationship between dopamine receptor blockade and cognitive performance in schizophrenia: a [11C]-raclopride PET study with aripiprazole
Taking Stock of Recent Clinical Research in Generalized Myasthenia Gravis: What Is the Potential Impact of New Therapies on Disease Management?